Finished Product Supply Agreement Sample Contracts
EX-10.1 7 d617354dex101.htm EX-10.1 FINISHED PRODUCT SUPPLY AGREEMENTFinished Product Supply Agreement • May 5th, 2020 • New York
THIS FINISHED PRODUCT SUPPLY AGREEMENT (this “Agreement”) dated as of October 8, 2003, and effective as of the Closing Date (the “Effective Date”) is made and entered into by and between Aventis Pharmaceuticals Inc., a company organized and existing under the laws of Delaware (“Aventis”), and Axcan Pharma Inc., a corporation organized and existing under the laws of Canada (“Axcan Pharma”, on behalf of itself and its Affiliates, collectively, the “Purchaser”). Capitalized terms used in this Agreement shall have the meanings ascribed to them in Article 1 hereof or as otherwise set forth herein; capitalized terms used herein without definition shall have the meanings ascribed to them in the Product Acquisition Agreement (as defined below).
Standard Contracts
AMENDMENT NO. 1 TO FINISHED PRODUCT SUPPLY AGREEMENTFinished Product Supply Agreement • April 19th, 2005 • Inyx Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (the “Amendment No. 1”) dated as of April 15, 2005 with an effective date of April 1, 2005 (the “Amendment No. 1 Effective Date”) to the Finished Product Supply Agreement (the “Supply Agreement”) dated as of March 5, 2004 and effective as of March 31, 2004, is made and entered into by and between Inyx, Inc. (“Inyx”), the assignee and successor in interest to Aventis Pharmaceuticals Inc. and its Affiliates (“Aventis”) and Aeropharm Technology, LLC, the successor in interest to Aeropharm Technology, Inc. (“Purchaser”). Capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in of the Supply Agreement, unless as otherwise provided herein.
RECITALSFinished Product Supply Agreement • March 26th, 2004 • Kos Pharmaceuticals Inc • Pharmaceutical preparations • New York
AMENDMENT TO THE FINISHED PRODUCT SUPPLY AGREEMENTFinished Product Supply Agreement • November 14th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations
This Amendment (the “Amendment”) is made and entered into as of August 26, 2005 by and between Janssen Pharmaceutica, NV, a business corporation organized under the Laws of Belgium, having its principal office at B-2340 Beerse, Turnhoutseweg 30, Belgium (hereinafter referred to as “Janssen”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600 College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as “Barrier”).
FINISHED PRODUCT SUPPLY AGREEMENTFinished Product Supply Agreement • July 18th, 2005 • Warner Chilcott CORP • New York
EXHIBIT 10.25 Confidential Execution Copy FINISHED PRODUCT SUPPLY AGREEMENT executed as of the date last below written (hereinafter referred to as "Effective Date") by and between JANSSEN PHARMACEUTICA, Naamloze Vennootschap, a business corporation...Finished Product Supply Agreement • February 1st, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations
** ] = PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. AN UNREDACTED VERSION OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FINISHED PRODUCT...Finished Product Supply Agreement • October 7th, 2008 • Axcan Intermediate Holdings Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
THIS FINISHED PRODUCT SUPPLY AGREEMENT (this “Agreement”) dated as of October 8, 2003, and effective as of the Closing Date (the “Effective Date”) is made and entered into by and between Aventis Pharmaceuticals Inc., a company organized and existing under the laws of Delaware (“Aventis”), and Axcan Pharma Inc., a corporation organized and existing under the laws of Canada (“Axcan Pharma”, on behalf of itself and its Affiliates, collectively, the “Purchaser”). Capitalized terms used in this Agreement shall have the meanings ascribed to them in Article 1 hereof or as otherwise set forth herein; capitalized terms used herein without definition shall have the meanings ascribed to them in the Product Acquisition Agreement (as defined below).
AMENDMENT NO. 1 TO THE FINISHED PRODUCT SUPPLY AGREEMENTFinished Product Supply Agreement • December 26th, 2013 • Aptalis Holdings Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Finished Product Supply Agreement (this “Amendment”) is entered into as of August 2, 2008 (the “Amendment Date”), by and between: